Interrogating molecular data for medulloblastoma risk stratification
Menée à partir de l'analyse de 136 échantillons tumoraux prélevés sur des patients atteints d'un médulloblastome (âge : 4 à 21 ans) puis validée sur 70 patients complémentaires, cette étude identifie une signature, basée sur des anomalies chromosomiques, permettant d'affiner le pronostic chez les patients atteints d'un médulloblastome avec non activation des voies de signalisation WNT et SHH (Sonic Hedgehog)
Medulloblastoma is the most common malignant paediatric brain tumour, with an incidence between 2·34 and 5·96 per million population. Early studies on medulloblastoma biology were largely inconclusive because of its molecular heterogeneity and the small size of the cohorts analysed. By contrast, more recent studies, based on a large number of internationally collected cases, have produced a deeper understanding of the molecular events that characterise medulloblastoma. Indeed, on the basis of gene expression, genetic aberrations, and DNA methylation, medulloblastoma is now classified into several molecular subgroups. The 2016 WHO Classification of Tumors of the Central Nervous System combines molecular and histological features for an innovative integrated diagnosis, thus allowing stratification of patients into four prognostic risk categories: favourable, standard, high, and very high risk.
The Lancet Oncology , commentaire en libre accès, 2017